Fully revised and updated, the report provides details of diagnostic imaging deals from 2016 to 2023.
The report provides a detailed understanding and analysis of how and why companies enter diagnostic imaging deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
The report includes collaboration, development, research and licensing deals.
This report contains a comprehensive listing of 567 diagnostic imaging deals announced since 2016 including financial terms where available including links to online deal records of actual diagnostic imaging partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of diagnostic imaging dealmaking.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in diagnostic imaging dealmaking since 2016.
Chapter 3 provides an overview of the leading diagnostic imaging deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in diagnostic imaging dealmaking with a brief summary followed by a comprehensive listing of diagnostic imaging deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of diagnostic imaging deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of diagnostic imaging partnering deals signed and announced since Jan 2016. The chapter is organized by specific diagnostic imaging technology type in focus.
The report also includes numerous table and figures that illustrate the trends and activities in diagnostic imaging deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Diagnostic Imaging Collaboration and Licensing Deals provides the reader with the following key benefits:• Understand deal trends since 2016
• Browse diagnostic imaging collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time
Report scopeDiagnostic Imaging Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of diagnostic imaging trends and structure of deals entered into by leading biopharma companies worldwide.
Diagnostic Imaging Collaboration and Licensing Deals includes:• Trends in diagnostic imaging dealmaking in the biopharma industry
• Directory of diagnostic imaging deal records covering pharmaceutical and biotechnology
• The leading diagnostic imaging deals by value
• Most active diagnostic imaging licensing dealmakers
Diagnostic Imaging Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?
Table of Contents
2.2. Diagnostic imaging deals over the years
2.3. Most active diagnostic imaging dealmakers
2.4. Diagnostic imaging deals by deal type
2.5. Diagnostic imaging deals by therapy area
2.6. Diagnostic imaging deals by industry sector
2.7. Deal terms for diagnostic imaging deals
2.7.1 Diagnostic imaging deals headline values
2.7.2 Diagnostic imaging deal upfront payments
2.7.3 Diagnostic imaging deal milestone payments
2.7.4 Diagnostic imaging royalty rates
3.2. Top diagnostic imaging deals by value
4.2. Most active diagnostic imaging dealmakers
4.3. Most active diagnostic imaging deals company profiles
5.2. Diagnostic imaging contracts dealmaking directory
Deal directory - Diagnostic imaging deals by deal type
Deal directory - Diagnostic imaging deals by therapy area
Deal type definitions
Figure 2: Active diagnostic imaging dealmaking activity - 2016 - 2023
Figure 3: Diagnostic imaging deals by deal type since 2016
Figure 4: Diagnostic imaging deals by therapy area since 2016
Figure 5: Diagnostic imaging deals by industry sector since 2016
Figure 6: Diagnostic imaging deals with a headline value
Figure 7: Diagnostic imaging deals with an upfront value
Figure 8: Diagnostic imaging deals with a milestone value
Figure 9: Diagnostic imaging deals with a royalty rate value
Figure 10: Top diagnostic imaging deals by value since 2016
Figure 11: Most active diagnostic imaging dealmakers 2016 - 2023
Figure 12: Diagnostic imaging deals by technology type since 2016
A selection of companies mentioned in this report includes:
- 3B Pharmaceuticals
- 3Derm Systems
- 3DR Labs
- 7D Surgical
- 22nd Century
- AAM Healthcare
- Abbott Laboratories
- Abramson Cancer Center
- Acacia Research
- Accudata Systems
- Acibadem University
- AC Immune
- ACIST Medical Systems
- Acoustic MedSystems
- Acutus Medical
- Advanced Accelerator Applications
- Advanced Animal Diagnostics
- Advanced Cell Diagnostics
- Advanced Chemistry Development
- Advanced Guidance Technologies
- Advanced Human Imaging
- Advanced Nuclear Medicine Ingredients
- Advanced Ultrasound Systems
- Agfa HealthCare
- Agilent Technologies
- AG Mednet
- Aiforia Technologies
- AIG Hospitals
- AI Metrics
- AIM Specialty Health
- Aircraft Medical
- Akoya Biosciences
- Albany Molecular Research
- Albert Einstein College of Medicine
- Albert Einstein Healthcare Network
- Alibaba Health
- Align Technology
- Allegheny Technologies
- Alpha Imaging
- Alpinion Medical Systems
- Alume Biosciences
- Alzeca Biosciences
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- Alzheimers Research UK
- Amag Pharmaceuticals
- Ambra Health
- Ambry Genetics
- AmCad BioMed
- A Menarini Diagnostics
- American Brain Tumor Association
- American College of Cardiology
- American College of Chest Physicians
- American Health Imaging
- American Migraine Foundation
- AMRA Medical
- Analytics 4 Life
- Andor Technology
- Antaros Medical
- Applied Spectral Imaging
- APRINOIA Therapeutics
- Arc Medical Design
- Aridea Solutions
- ARTMS Product
- ARUP Laboratories
- Ashvattha Therapeutics
- Aspect Imaging
- Aspen Imaging Healthcare
- Athinoula A Martinos Center for Biomedical Imaging
- Austin Health
- Avantis Medical Systems
- Avicenna Technology
- AVRA Surgical
- Aytu BioPharma
- AZ Sint Lucas Hospital
- BAMF Health
- Banner Health
- Baptist Health Care
- Baxter International
- Bay Labs
- Baylor College
- Baylor College of Medicine
- BC Technical
- Beijing Podconley Pharmaceutical Technology and Development
- Bethyl Laboratories
- Biim Ultrasound
- Bill and Melinda Gates Foundation
- BioArctic Neuroscience
- Biolife Science
- BioMark Diagnostics
- Bioscience Pharma Partners
- Biotechnology Innovation Organization
- BioTek Instruments
- BJC HealthCare
- BlackThorn Therapeutics
- Blue Earth Diagnostics
- Boehringer Ingelheim
- Boston Medical Center
- Boston Scientific
- Bracco Diagnostics
- Bracco Imaging
- Brain & Behavior Research Foundation
- BRAIN Initiative
- Brain Scientific
- BriaCell Therapeutics
- Brigham and Women's Hospital
- Broad Institute
- Bruker AXS
- Bruker Energy & Supercon Technologies (BEST)
- Butantan Institute
- Butterfly Network
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Collaborative R&D
- Contract service
- Equity purchase
- Joint venture
- Royalty financing
- Spin out
- Sub license
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.